SlideShare ist ein Scribd-Unternehmen logo
1 von 14
SEVERITY AND SERIOUSNESS
ASSESSMENT OF ADR
Dr. Ramesh Bhandari
Asst. Professor
Department of Pharmacy Practice,
KLE College of Pharmacy, Belagavi
SEVERITY
•The term severity is often used to describe the
intensity of a medical event.
•Severity assessment categorizes the ADRs as
mild, moderate or severe based on the steps taken
for the management of the ADRs.
SEVERITY
• KARCH AND LASAGNA classified severity into minor, moderate,
severe and lethal as defined below:
 Minor: No antidote, treatment or prolongation of hospitalization
required.
 Moderate: A change in drug therapy (e.g.: modified dosage, addition
of a drug), but not necessarily discontinuation of the drug is required;
hospitalization may be prolonged, or specific treatment may be
required.
 Severe: Potentially life threatening, causing permanent damage or
requiring intensive medical care. Requires drug discontinuation.
 Lethal: Directly or indirectly contributes to the death of the patient.
MODIFIED HARTWIG’S AND SIEGELASSESSMENT SCALE
• Hartwig et. al robustly categorized ADR severity into seven
levels according to clinical consequence, including resultant
harm and intensity of medical intervention required.
oLevel 1 and 2 fall under mild category
oLevel 3 and 4 fall under moderate category
oLevel 5, 6 and 7 fall under category severe category.
Modified Hartwig and Siegel
• Mild:
Level 1: The ADR requires no change in treatment with the
suspected drug
Level 2: The ADR requires that the suspected drug be withheld,
discontinued or otherwise changed. NO antidote or other
treatment is required, and there is no increase in length of stay.
Modified Hartwig and Siegel
• Moderate:
Level 3: The ADR requires that the suspected drug be withheld,
discontinued or otherwise changed, and / or an antidote or
other treatment is required. There is no increase in length of
stay
Level 4 (a): Any level 3 ADR that increases length of stay by at
least one day
Level 4 (b): The ADR is the reason for admission.
Modified Hartwig and Siegel
• Severe:
Level 5: Any level 4 ADR that requires intensive medical care.
Level 6: The ADR causes permanent harm to the patient
Level 7: The ADR either directly or indirectly leads to the death
of the patient.
SERIOUSNESS CLASSIFICATION
• A serious adverse event or reaction is any untoward medical
occurrence that at any dose:
 Results in death
 Is life threatening
 Requires inpatient hospitalization or prolong hospitalization
 Results in persistent or significant disability
 Is a congenital anomaly/birth defect
PREVENTABILITY AND
PREDICTABILITY OF ADRs
PREVENTABILITY OFADRs
• Schumock and Thornton criteria:
• It has three sections namely definitely preventable, probably preventable and not-preventable.
• Section A comprises of five questions while section B has four questions.
• All the answers are categorized as “yes” or “no”.
• ADRs are “definitely preventable” if answer was “yes” to one or more questions in section A.
• If answers are all negative (“no”), then proceed to section B
• ADRs are “probably preventable” if answer was “yes” to one or more questions in section B.
• If answers were all negative then proceed to section C.
• In section C, the ADRs are not-preventable.
PREDICTABILITY Of ADRs
• Type A (Predictable):
Extension of pharmacological effect
Often predictable and dose dependent
Example: Dry mouth induced by anti-cholinergics.
• Type B (Non-predictable):
Idiosyncratic or immunologic reactions
Rare and unpredictable
Example: Penicillin induced anaphylactic shock.
REFERENCES
1. Karch FE, Lasagna L. Adverse drug reactions. JAMA. 1975;
234(12):1236
2. S. K. Gupta. Textbook of Pharmacovigilance. 2nd Edition. Jaypee
Brothers Medical Publishers. 2019.
THANK YOU

Weitere ähnliche Inhalte

Was ist angesagt?

Standardized and MedDRA Queries
Standardized and MedDRA QueriesStandardized and MedDRA Queries
Standardized and MedDRA Queries
Rajat Garg
 

Was ist angesagt? (20)

Methods of causality assessment
Methods of causality assessmentMethods of causality assessment
Methods of causality assessment
 
WHO International Drug Monitoring Program
WHO International Drug Monitoring ProgramWHO International Drug Monitoring Program
WHO International Drug Monitoring Program
 
Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction Detection and Reporting of Adverse Reaction
Detection and Reporting of Adverse Reaction
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
Establishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptxEstablishing Pharmacovigilance Centres In Hospital.pptx
Establishing Pharmacovigilance Centres In Hospital.pptx
 
History of Pharmacovigilance
History of PharmacovigilanceHistory of Pharmacovigilance
History of Pharmacovigilance
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 
History n progress of pv
History n progress of pvHistory n progress of pv
History n progress of pv
 
History and progress of pharmacovigilance
History and progress of pharmacovigilanceHistory and progress of pharmacovigilance
History and progress of pharmacovigilance
 
Causality assessment scale
Causality assessment scaleCausality assessment scale
Causality assessment scale
 
Pharmacovigilance programme of india
Pharmacovigilance programme of indiaPharmacovigilance programme of india
Pharmacovigilance programme of india
 
Med-DRA
Med-DRAMed-DRA
Med-DRA
 
CONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATIONCONTRACT RESEARCH ORGANIZATION
CONTRACT RESEARCH ORGANIZATION
 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilance
 
WHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptxWHO international drug monitoring programme.pptx
WHO international drug monitoring programme.pptx
 
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...
Anatomic Therapeutic Chemical Classification, Defined daily dose, Drug utilis...
 
2.3  Daily defined doses.pptx
2.3  Daily defined doses.pptx2.3  Daily defined doses.pptx
2.3  Daily defined doses.pptx
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
 
Schedule y
Schedule ySchedule y
Schedule y
 
Standardized and MedDRA Queries
Standardized and MedDRA QueriesStandardized and MedDRA Queries
Standardized and MedDRA Queries
 

Ähnlich wie Severity, seriousness, predictability and preventability assessment

Changing Anti-Retroviral Therapy
Changing Anti-Retroviral TherapyChanging Anti-Retroviral Therapy
Changing Anti-Retroviral Therapy
shabeel pn
 
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat
David Ngogoyo
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsn
David Ngogoyo
 
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptxAdverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Deepali69
 

Ähnlich wie Severity, seriousness, predictability and preventability assessment (20)

ADVERSE DRUG REACTION
ADVERSE DRUG  REACTIONADVERSE DRUG  REACTION
ADVERSE DRUG REACTION
 
Collection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSRCollection, Processing and Reporting of ICSR
Collection, Processing and Reporting of ICSR
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptx
 
The Prospective Study Of Adverse Drug Reactions in Surgical Wards of a Tertia...
The Prospective Study Of Adverse Drug Reactions in Surgical Wards of a Tertia...The Prospective Study Of Adverse Drug Reactions in Surgical Wards of a Tertia...
The Prospective Study Of Adverse Drug Reactions in Surgical Wards of a Tertia...
 
Changing Anti-Retroviral Therapy
Changing Anti-Retroviral TherapyChanging Anti-Retroviral Therapy
Changing Anti-Retroviral Therapy
 
03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat03.02 management of patients on antiretroviral drugs initiat
03.02 management of patients on antiretroviral drugs initiat
 
02.02 adult art initiation gsn
02.02 adult  art initiation gsn02.02 adult  art initiation gsn
02.02 adult art initiation gsn
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
 
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptxAdverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
Adverse-Drug-Reactions-Patient-Level-by-Prof-Jamie-Coleman.pptx
 
Handout adr
Handout adrHandout adr
Handout adr
 
Adverse drug reaction for BPH
Adverse drug reaction for BPHAdverse drug reaction for BPH
Adverse drug reaction for BPH
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Causality assessment scales
Causality assessment scalesCausality assessment scales
Causality assessment scales
 
ADR and pharmacovigillance
ADR and pharmacovigillanceADR and pharmacovigillance
ADR and pharmacovigillance
 
adverse drug rxn.ppt
adverse drug rxn.pptadverse drug rxn.ppt
adverse drug rxn.ppt
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Adverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & ReportingAdverse Drug Reactions - Identifying, Causality & Reporting
Adverse Drug Reactions - Identifying, Causality & Reporting
 
pharmaceutical care
pharmaceutical carepharmaceutical care
pharmaceutical care
 
ADRppt.pptx
ADRppt.pptxADRppt.pptx
ADRppt.pptx
 

Mehr von Dr. Ramesh Bhandari

Mehr von Dr. Ramesh Bhandari (20)

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
 
Microbiology
MicrobiologyMicrobiology
Microbiology
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
 
Nutrition
NutritionNutrition
Nutrition
 
Mother and child health
Mother and child healthMother and child health
Mother and child health
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
 
Detection and monitoring of ADRs
Detection and monitoring of ADRsDetection and monitoring of ADRs
Detection and monitoring of ADRs
 
Reporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistReporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacist
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 

Kürzlich hochgeladen

Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
MateoGardella
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Kürzlich hochgeladen (20)

Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 

Severity, seriousness, predictability and preventability assessment

  • 1. SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR Dr. Ramesh Bhandari Asst. Professor Department of Pharmacy Practice, KLE College of Pharmacy, Belagavi
  • 2. SEVERITY •The term severity is often used to describe the intensity of a medical event. •Severity assessment categorizes the ADRs as mild, moderate or severe based on the steps taken for the management of the ADRs.
  • 3. SEVERITY • KARCH AND LASAGNA classified severity into minor, moderate, severe and lethal as defined below:  Minor: No antidote, treatment or prolongation of hospitalization required.  Moderate: A change in drug therapy (e.g.: modified dosage, addition of a drug), but not necessarily discontinuation of the drug is required; hospitalization may be prolonged, or specific treatment may be required.  Severe: Potentially life threatening, causing permanent damage or requiring intensive medical care. Requires drug discontinuation.  Lethal: Directly or indirectly contributes to the death of the patient.
  • 4. MODIFIED HARTWIG’S AND SIEGELASSESSMENT SCALE • Hartwig et. al robustly categorized ADR severity into seven levels according to clinical consequence, including resultant harm and intensity of medical intervention required. oLevel 1 and 2 fall under mild category oLevel 3 and 4 fall under moderate category oLevel 5, 6 and 7 fall under category severe category.
  • 5. Modified Hartwig and Siegel • Mild: Level 1: The ADR requires no change in treatment with the suspected drug Level 2: The ADR requires that the suspected drug be withheld, discontinued or otherwise changed. NO antidote or other treatment is required, and there is no increase in length of stay.
  • 6. Modified Hartwig and Siegel • Moderate: Level 3: The ADR requires that the suspected drug be withheld, discontinued or otherwise changed, and / or an antidote or other treatment is required. There is no increase in length of stay Level 4 (a): Any level 3 ADR that increases length of stay by at least one day Level 4 (b): The ADR is the reason for admission.
  • 7. Modified Hartwig and Siegel • Severe: Level 5: Any level 4 ADR that requires intensive medical care. Level 6: The ADR causes permanent harm to the patient Level 7: The ADR either directly or indirectly leads to the death of the patient.
  • 8. SERIOUSNESS CLASSIFICATION • A serious adverse event or reaction is any untoward medical occurrence that at any dose:  Results in death  Is life threatening  Requires inpatient hospitalization or prolong hospitalization  Results in persistent or significant disability  Is a congenital anomaly/birth defect
  • 10. PREVENTABILITY OFADRs • Schumock and Thornton criteria: • It has three sections namely definitely preventable, probably preventable and not-preventable. • Section A comprises of five questions while section B has four questions. • All the answers are categorized as “yes” or “no”. • ADRs are “definitely preventable” if answer was “yes” to one or more questions in section A. • If answers are all negative (“no”), then proceed to section B • ADRs are “probably preventable” if answer was “yes” to one or more questions in section B. • If answers were all negative then proceed to section C. • In section C, the ADRs are not-preventable.
  • 11.
  • 12. PREDICTABILITY Of ADRs • Type A (Predictable): Extension of pharmacological effect Often predictable and dose dependent Example: Dry mouth induced by anti-cholinergics. • Type B (Non-predictable): Idiosyncratic or immunologic reactions Rare and unpredictable Example: Penicillin induced anaphylactic shock.
  • 13. REFERENCES 1. Karch FE, Lasagna L. Adverse drug reactions. JAMA. 1975; 234(12):1236 2. S. K. Gupta. Textbook of Pharmacovigilance. 2nd Edition. Jaypee Brothers Medical Publishers. 2019.